THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
The introduction of tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR) inhibitors to the clinic has resulted in an improvement in the treatment of non small cell lung cancer (NSCLC). However, many patients treated with EGFR TKIs do not respond to therapy. The burd...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
UKnowledge
2009
|
| Subjects: | |
| Online Access: | http://uknowledge.uky.edu/gradschool_diss/726 http://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1729&context=gradschool_diss |